Robotic Extended Pelvic Lymphadenectomy for Intermediate- and High-Risk Prostate Cancer

被引:50
|
作者
Yuh, Bertram E. [1 ]
Ruel, Nora H. [1 ]
Mejia, Rosa [1 ]
Wilson, Chelsea M. [1 ]
Wilson, Timothy G. [1 ]
机构
[1] City Hope Natl Canc Ctr, Duarte, CA 90017 USA
关键词
Pelvic lymphadenectomy; Robotics; Positive lymph nodes; Prostate Cancer; LYMPH-NODE DISSECTION; RADICAL PROSTATECTOMY; IMPACT; METASTASES; MEN; YIELD;
D O I
10.1016/j.eururo.2012.01.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Accurate staging of prostate cancer is enhanced by a thorough evaluation of the pelvic lymph nodes. Limited data are available regarding robotic extended pelvic lymphadenectomy (PLA) in this setting. Objective: Analyze our experience performing robotic extended PLA. Design, setting, and participants: A total of 143 consecutive men with intermediate-or high-risk clinically localized adenocarcinoma of the prostate underwent robotic extended PLA and radical prostatectomy between September 2010 and November 2011 by a single surgeon. Surgical procedure: Lymph node packets were sent separately from bilateral common, external, and internal iliacs, obturators, node of Cloquet, and anterior prostatic fat. Measurements: Descriptive statistics were used to summarize lymph node yields and positive nodes. Clinical variables were examined in logistic regression models to predict lymph node positivity. Results and limitations: Median lymph node yield was 20 (range: 9-65, interquartile range: 15-25). Eighteen patients (13%) were found to have metastatic prostate cancer in the lymph nodes. The mean number of positive nodes foundwas 2.9 (range: 1-11). In 14 of 18 node-positive patients (78%), the extent of nodal invasion was outside the boundaries of a limited PLA. For four patients with positive nodes (22%), prostate biopsy predicted unilateral disease but PLA revealed contralateral positive lymph nodes. A total of 82% of patients experienced no complications, and most Clavien grade 1-2 complications consisted of anastomotic leakage, urinary retention, ileus, and lymphocele. Only 4% of patients experienced a grade 3 complication. Under multivariate regression analysis, prostate-specific antigen (PSA), clinical stage, and maximum biopsy core tumor volume were identified as significant predictors of finding positive pelvic lymph nodes (area under the curve: 91%). The main limitations include short follow-up and lack of randomization. Conclusions: Robotic extended bilateral PLA for prostate cancer up to the common iliac bifurcation increases nodal yield and positive nodal rate and can be performed safely. PSA, clinical stage, and maximum biopsy core volume are predictors for lymph node invasion. Long-term follow-up is needed to evaluate for therapeutic benefit. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:1004 / 1010
页数:7
相关论文
共 50 条
  • [21] Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer
    Loblaw, Andrew
    CANCER JOURNAL, 2020, 26 (01): : 38 - 42
  • [22] APPLICABILITY ANALYSIS OF FOCAL THERAPY TO INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Matsuoka, Yoh
    Numao, Noboru
    Saito, Kazutaka
    Tanaka, Hiroshi
    Inoue, Masaharu
    Ito, Masaya
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Fujii, Yasuhisa
    Kihara, Kazunori
    JOURNAL OF UROLOGY, 2016, 195 (04): : E195 - E195
  • [23] Hypofractionated versus conventional radiotherapy in intermediate- to high-risk prostate cancer
    Guo, W.
    Gao, X. S.
    Gu, X. B.
    Ma, M. W.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S716 - S716
  • [24] A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
    Armstrong, Andrew J.
    Netto, George J.
    Rudek, Michelle A.
    Halabi, Susan
    Wood, David P.
    Creel, Patricia A.
    Mundy, Kelly
    Davis, S. Lindsay
    Wang, Ting
    Albadine, Roula
    Schultz, Luciana
    Partin, Alan W.
    Jimeno, Antonio
    Fedor, Helen
    Febbo, Phillip G.
    George, Daniel J.
    Gurganus, Robin
    De Marzo, Angelo M.
    Carducci, Michael A.
    CLINICAL CANCER RESEARCH, 2010, 16 (11) : 3057 - 3066
  • [25] Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer
    Chan, June M.
    Oh, William K.
    Xie, Wanling
    Regan, Meredith M.
    Stampfer, Meir J.
    King, Irena B.
    Abe, Miyako
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3577 - 3583
  • [26] THE EXTENT OF PELVIC LYMPH NODE DISSECTION CORRELATES WITH THE BIOCHEMICAL RECURRENCE RATE IN PATIENTS WITH INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Schiavina, R.
    Baccos, A.
    Pernetti, P.
    Zukerman, Z.
    Salama, A.
    Vagnoni, V.
    Borghesi, M.
    Romagnoli, D.
    Barbieri, B.
    Brunocilla, E.
    Bertaccini, A.
    Concetti, S.
    Martorana, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 185 - 185
  • [27] The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer
    Schiavina, Riccardo
    Manferrari, Fabio
    Garofalo, Marco
    Bertaccini, Alessandro
    Vagnoni, Valerio
    Guidi, Mascia
    Borghesi, Marco
    Baccos, Alessandro
    Morselli-Labate, Antonio Maria
    Concetti, Sergio
    Martorana, Giuseppe
    BJU INTERNATIONAL, 2011, 108 (08) : 1262 - 1268
  • [28] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials
    Nguyen, Paul L.
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2055 - 2056
  • [29] Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer
    Hu, Ju-Chuan
    Hung, Sheng-Chun
    Ou, Yen-Chuan
    ANTICANCER RESEARCH, 2017, 37 (06) : 3143 - 3150
  • [30] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials
    Roach, Mack, III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3816 - 3817